CMS released its CY2027 outpatient and ASC proposed rule on July 2. Twelve days later it released the CY2027 physician fee schedule. The comment windows close on different dates — August 31 for the outpatient rule, September 14 for the physician rule — and most of the trade coverage has handled them as two separate stories, one about facilities and one about physicians. Read together, they are one story.
Start with the facility side. A 2.4% payment update to both OPPS and ASC rates, built from a 3.2% market basket increase less a 0.8 percentage point productivity adjustment. A new ASC conversion factor of $57.766 for centers meeting quality reporting requirements, up from $56.322, and $56.638 for those that do not. Another 618 surgical codes proposed for addition to the ASC covered procedures list. And 637 procedures proposed for removal from the inpatient-only (IPO) list, roughly half of the 1,438 still on it. The remaining 801 — the more clinically complex neurological, cardiovascular and transplant families — come off in CY2028, the final year of the three-year wind-down CMS finalized last November. The IPO list ceases to exist as of January 1, 2028. CMS estimates total Medicare payments to ASCs would reach roughly $9.9 billion, about $520 million above 2026.
One qualification before the comparison, because it matters: not every facility gets a raise. Hospitals face 340B drugs repriced from ASP plus 6% to ASP minus 33.4%, and an increase in the conversion factor offset from 0.5% to 3% to accelerate recovery of the 340B remedy. CMS puts the hit to affected hospitals at $2.3 billion and the net OPPS increase at 1.9%. The clean winner in this rule is not the hospital outpatient department. It is the ASC.
Now the physician side. The conversion factor drops 1.68% for most clinicians, to $32.84, and 1.19% for those in qualifying alternative payment models, to $33.17 — largely because the one-year 2.5% increase Congress provided for 2026 expires. On top of that, CMS’s own specialty-level impact estimate has orthopedic surgery losing a further 7% from the revaluation of work, practice expense and malpractice RVUs, a budget-neutral redistribution that sits separately from the conversion factor cut. Work RVUs for major joint replacement fall by as much as 20.8%. The ASC gets a raise. The surgeon takes a cut. Same agency, twelve days apart.
There is a smaller detail worth flagging because it contradicts the headline number. Four of the highest-volume ASC pain management codes are proposed for reductions despite that 2.4% average update. Lumbar facet radiofrequency ablation (64635) would go from $948.66 to $908.27. Transforaminal epidural steroid injection, lumbar/sacral (64483), from $485.51 to $466.96. Forty dollars and nineteen dollars sound trivial until you multiply them by the case volume of an interventional pain practice.
So what does this mean for those of us selling implants?
The buyer keeps moving. Surgeon preference still opens the door — that has not changed and probably will not. But the signature increasingly belongs to an ASC that owns its own margin per case and knows exactly what your tray costs it. Reps who still sell exclusively to the surgeon are selling to the person with the least budget authority in the room.
Implant cost becomes personal. When the surgeon is also an owner, every dollar on the implant line comes out of a distribution he receives. That is a very different negotiation from one where the hospital absorbs the cost. It is also the reason surgeon-owners tend to consolidate down to two vendors instead of five.
List price is finished as a conversation. What sells now is a per-case number, and the components of it: consignment burden, set size, single-use instrumentation, turnaround, financing terms. A company that cannot produce that number on request looks expensive whether it is or not.
Volume will not rescue price. In the Medicare fee-for-service population, outpatient spine procedures grew roughly 193% between 2010 and 2021, with ASC cases compounding at 15.7% a year. Between 2021 and 2024, the ASC share of spine surgeries rose about 8% year over year, according to AcuityMD. Everyone points at that curve as the growth story. It is also the mechanism of the cuts. Cases migrate, claims data shows the migration, CMS revalues the code to match the cheaper setting, more cases migrate. The loop feeds itself, and the 2027 rule is simply the loop running on schedule.
For European manufacturers reading this from a distance: the same pressure arrives here, later and through tenders rather than through CMS, but it arrives.
One caveat. These are proposed rules. The final outpatient rule lands in November, and CMS has pulled back before under pressure — last year it proposed raising the 340B conversion factor offset to 2% and did not finalize it. Nobody should be rewriting a 2027 budget on a July draft. But the direction of travel — volume out of the hospital, value out of the surgeon’s line — is not in doubt, and it has been consistent for four years. The companies that do well in 2027 will not necessarily be the ones with the best screw. They will be the ones who can walk into an ASC, put a per-case cost on the table, and defend it.
###
SOURCES: CY2027 OPPS/ASC proposed rule, CMS-1850-P, issued July 2 and published in the Federal Register on July 7, 2026; comments due August 31, 2026. CY2027 Medicare Physician Fee Schedule proposed rule, issued July 14 and published July 16, 2026; comments due September 14, 2026. ASC code-level rates from Addenda AA and BB, not from the rule text. CMS’s fact sheet cites 638 IPO removals where the rule text and most published summaries cite 637; the figure used here is 637, which reconciles with the 801 procedures remaining. Specialty impact estimates from Table D-B5 of the PFS proposed rule. Spine volume growth from Growing utilization of ambulatory spine surgery in Medicare patients from 2010–2021, North American Spine Society Journal, March 2024, covering HCPCS ranges 22010–22899 and 62380–63103 in Medicare Part B fee-for-service claims. ASC share data from AcuityMD, presented at AAOS 2025 and covering 2021 through 2024.
Legal Disclaimer:
Content published on SPINEMarketGroup (thespinemarketgroup.com) is provided for informational purposes only and on an “as is” basis, without warranties of any kind. We do not guarantee the accuracy, completeness, legality, or reliability of any information, images, videos, links, or third-party materials featured on the site. Any views or claims expressed in contributed content or press releases belong to their respective authors or sources. For copyright concerns, factual corrections, or content-related complaints, please contact us directly for review.